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Aims The relevance of lipoprotein(a) [Lp(a)] concentrations and low-molecular-weight (LMW) apo(a) phenotypes in periph-
eral arterial disease (PAD) has only been investigated by few studies. Therefore, we analysed this association in three
independent cohorts and performed a Mendelian Randomization approach using instrumental variable regression.
Methods
and results
Lp(a) concentrations, apo(a) phenotypes, and one SNP in the LPA gene (rs10455872) were measured in the CAVASIC
study, including 241 male patients with intermittent claudication and 246 age- and diabetes-matched controls as well
as in the two population-based studies KORA F3 (n ¼ 3184) and KORA F4 (n ¼ 3080). In KORA F3/F4, 109/80
persons suffered from intermittent claudication, 200/144 from PAD, and 128/103 showed an ankle–brachial index
(ABI) ,0.9. In CAVASIC, adjusted logistic regression analyses revealed significant associations between an increase of
log-Lp(a) per one standard deviation (SD) (OR ¼ 1.28, P ¼ 0.02) as well as LMW apo(a) phenotypes and symptomatic
PAD (OR ¼ 1.65, P ¼ 0.03). Linear regression models with continuous ABI showed a significant association in the com-
bined analyses of KORA F3/F4: an increase in log-Lp(a) per one SD (b ¼ 20.006, P ¼ 0.005) and the presence of LMW
apo(a) phenotypes (b ¼ 20.011, P ¼ 0.02) or the minor allele of rs10455872 (ß ¼ 20.016, P ¼ 0.03) were associated
with a decrease in ABI in the fully adjusted linear and instrumental variable regression models.
Conclusion Analyses in three independent populations showed significant associations of Lp(a) concentrations, LMW apo(a) pheno-
types, and rs10455872 with PAD. This points to a causal relationship between Lp(a) and PAD since the genetically deter-
mined apo(a) phenotypes and SNP alleles are indeed associated with PAD.
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1. Introduction
Lipoprotein(a) [Lp(a)] consists of a low-density lipoprotein molecule
that is covalently connected to the high-molecular-weight glycoprotein
apolipoprotein(a) [apo(a)]. Plasma concentrations of Lp(a) are deter-
mined to a large extent by the size of the apo(a) isoforms, which are
expressed by a copy number variation of the LPA gene, varying
between 11 and .50 repeats of the kringle-IV domain.1 The apo(a)
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size polymorphism determines between 30 and 70% of the variance
of Lp(a) concentrations depending on the population investigated.1
An inverse relationship was found between the apo(a) isoform size
and Lp(a) concentrations.2 Both, high Lp(a) concentrations and a low
molecular weight (LMW) of apo(a) phenotypes are associated with car-
diovascular disease (CVD).3 –6 The pathophysiological role of Lp(a)
is not fully understood yet but it has been reported to possess athero-
genic and prothrombotic properties (reviewed in Kronenberg and
Utermann1). Moreover, apo(a) has a high homology with plasminogen
and in vitro studies reported interferences with the blood clotting and
fibrinolytic cascades.1
Peripheral arterial disease (PAD) is a common manifestation of vascu-
lar disease resulting from atherosclerotic occlusions of the lower ex-
tremities. Depending on the definition of PAD, the prevalence ranges
between 4 and 14% in the general population7 and between 15 and
30% in adults above 60 years.8,9 Symptomatic PAD clinically presents
as intermittent claudication which is defined as pain in the calf muscles
that occurs when walking and is relieved by a period of rest.7 About
one-third of all PAD patients show classical symptoms of intermittent
claudication while asymptomatic PAD can be assessed by measuring
the ankle–brachial index (ABI).10 Both symptomatic and asymptomatic
PAD markedly increases the risk of fatal and non-fatal cardiovascular
events and mortality.8,10– 12 These observations triggered the search
for related risk factors toenableearly diagnosis especially for asymptom-
atic PAD to improve possibilities for an early intervention before fatal
events occur. However, the possible relevance of Lp(a) concentrations
and the presence of LMW apo(a) phenotypes in PAD patients have only
been addressed by a few studies so far. Therefore, we investigated the
association between Lp(a) concentrations, apo(a) phenotypes, and
symptomatic as well as asymptomatic PAD determined by the ABI in a
diseased population and two large population-based cohorts. More-
over, since apo(a) phenotypes and the SNP rs10455872 within the
LPA gene were determined for each of the investigated cohorts, it was
possible to apply a Mendelian Randomization approach to evaluate a pu-
tative causal effect of Lp(a) on PAD which is otherwise hardly possible
using conventional epidemiological methods.
2. Methods
2.1 Study description and clinical
characterization
In line with the Declaration of Helsinki, approval to the examination proto-
col for all three studies was given by the Ethics Committee and all partici-
pants provided written informed consent. A detailed description of the
study populations can be found in the Supplementary material online.
Shortly, the CAVASIC Study is a case–control study to explore the occur-
rence and determinants of CVD in male patients with intermittent claudi-
cation.13,14 Patients were included consecutively when presenting with
chronic intermittent claudication according to the criteria of Fontaine
(PAD IIa or IIb) or a history of intermittent claudication, irrespective of
former treatment procedures (bypass surgery or intervention). Overall,
249 patients and 251 age-and type-2 diabetes-matched controls were
enrolled between 2002 and 2006. Lp(a) concentrations and LMW apo(a)
phenotypes were measured in 241 patients and 246 controls and all
subsequent data analyses included in this manuscript are based on these
487 individuals.
KORA F3 and KORA F4 are population-based follow-up studies recruited
from the KORA S3 and S4 surveys and representative for the general popu-
lation in Augsburg, Southern Germany. KORA F3 was carried out between
2004 and 2005 and a total of 3184 subjects participated. KORA F4 was
conducted between 2006 and 2008 and a total of 3080 individuals were
finally included.15,16 Lp(a) concentrations and LMW apo(a) phenotypes
were measured in 3156 participants in KORA F3 and 3061 participants in
KORA F4. In the KORA studies, PAD was defined as symptomatic disease
according to the Edinburgh questionnaire or asymptomatic disease
(ABI,0.90) or both. Moreover, dichotomous outcome variables for
patients presenting with ABI values ,0.90 or with intermittent claudication
were computed. A detailed description of the ABI measurement can be
found in the Supplementary material online.
2.2 Lp(a) measurement, apo(a) phenotyping,
and SNP genotyping
Lp(a) quantification was performed with a double-antibody ELISA and
apo(a) phenotyping by SDS–agarose gel electrophoresis (for details refer
Kronenberg et al.17). Apo(a) phenotypes were classified as low (LMW)-
and high-molecular-weight (HMW) phenotypes.1 The LMW group included
all subjects with at least one apo(a) isoform with 11–22 KIV repeats; the
HMW group included all subjects having only isoforms with .22 KIV
repeats. If two apo(a) isoforms were detectable, we used only the smaller
apo(a) isoform for categorization as discussed earlier.18 In addition, the
SNP rs10455872 within the LPA gene that has already been used in Mendel-
ian randomization studies of Lp(a)19 was investigated in each of the study
populations (for details see Supplementary material online). The SNP was
in Hardy–Weinberg Equilibrium in all three studies (all P-values from the
exact test. 0.07). In all analyses of this SNP, an additive inheritance model
was assumed.
2.3 Statistical analysis
In CAVASIC, dichotomous and continuous variables were compared by
x2 test, unpaired t-test or Mann–Whitney U tests as appropriate. To
assess the causal association of Lp(a) on the respective PAD and/or
ABI outcome variables, three different levels of analyses were applied
(Figure 1): (i) association of Lp(a) concentrations on PAD/ABI; (ii) association
of LMW apo(a) phenotypes and rs10455872 on PAD/ABI; and (iii) in-
strumental variable (IV) regression analyses. More specifically, logistic re-
gression analyses were applied to evaluate the association between
log-transformed Lp(a) concentrations, apo(a) phenotypes, rs10455872,
and the dichotomous outcome variables. The odds ratios (ORs) and beta
estimates correspond to an increment of one standard deviation of
log-Lp(a) (SDlog-Lp(a)) in all analyses. Outcomes were PAD (presence of
intermittent claudication) defined by the case–control status in the
CAVASIC Study. In KORA, dichotomous outcomes were either the presence
orabsence of intermittent claudication or an ABI,/≥0.90 or both (defined as
PAD). Furthermore, linear regression analyses were carried out to assess the
association between log-Lp(a), LMW apo(a) phenotypes, and rs10455872 on
ABI as a continuous variable. To obtain a combined estimate for KORA F3 and
KORA F4, logistic and linear mixed models were applied.
Nonlinear P-Splines were used to check for linearityof Lp(a) in both linear
and logistic regression analyses.20 Since different cutpoints have been dis-
cussed for Lp(a) to dichotomize into high- and low-risk groups, optimal cut-
points were derived for all three studies by minimizing the Akaike
information criterion (AIC). As a sensitivity analysis, estimates are addition-
ally given for the most established cutpoints at 30 and 50 mg/dL. Further sen-
sitivity analyses were performed applying different exclusion criteria:
excluding individuals with prevalent CVDs and excluding individuals with
ABI values above 1.30. Furthermore, Lp(a)-adjusted analyses of apo(a) phe-
notypes on ABI/PAD were performed.
All models shown are based on those individuals with available data on
Lp(a) and apo(a) phenotypes and adjusted for age and/or sex. Extended
models were additionally adjusted for a number of variables including the
classical risk factors for PAD.
To investigate a putative causal effect of Lp(a) on PAD, IV regression ana-
lysis wasperformed usingLMWapo(a)phenotypes and theSNP rs10455872
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as the IVs on log-Lp(a). A two-stage least-squares regression method was
applied that regresses the LMW- and SNP-predicted log-Lp(a) values on
the respective outcome variables (see Supplementary material online for
details). To exclude a pleiotropic effect of LMW apo(a) phenotypes, we
excluded upfront an association between LMW apo(a) phenotypes and clas-
sical risk factors or markers for PAD (data not shown).
Statistical analyses were performed using SPSS version 18.0, R version
2.15.2, and STATA version 11.
3. Results
3.1 Symptomatic PAD in the CAVASIC
case–control study
Table 1 gives the characteristics of the CAVASIC Study including 241
patients with symptomatic PAD and 246 age- and T2DM-matched con-
trols. As expected, patients with PAD were more often smokers or
Figure 1 Chart illustrating the Mendelian Randomization approach based on different levels of analyses: regression of Lp(a) on PAD/ABI yielding the
observed estimate (A); regression of LMW apo(a) phenotypes or SNP rs10455872 on PAD/ABI (B), and IV regression analyses (in grey boxes), which is
a two-stage least-squares method, predicting Lp(a) levels from LMW apo(a) phenotypes and SNP rs10455872 (first stage IV regression) and regressing
these predicted values on PAD/ABI (C).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 General and clinical characteristics of controls and patients with PAD of the CAVASIC study and the two
population-based studies KORA F3 and F4
Controls (n 5 246) PAD (n 5 241) P-valuea KORA F3 (n 5 3157) KORA F4 (n 5 3061)
Age (years) 56+9 58+6 0.87 57+13 56+13
Sex (male), n (%) 246 (100) 241 (100) – 1545 (48.5) 1478 (48.3)
Diabetes mellitus, n (%) 41 (16.7) 38 (15.8) 0.79 258 (8.1) 215 (7)
Current smoking, n (%) 29 (11.8) 124 (52.1) ,0.001 551 (17.5) 547 (17.9)
Hypertension, n (%) 146 (59.6) 208 (86.3) ,0.001 1589 (50.2) 1175 (38.3)
Cardiovascular disease, n (%) 18 (7.3) 76 (31.5) ,0.001 308 (9.7) 265 (8.7)
Ankle–brachial index 1.07+0.12 0.72+0.23 ,0.001 1.13+0.15 1.15+0.16b
(1.00/1.08/1.15) (0.54/0.70/0.89) (1.05/1.13/1.20) (1.08/1.16/1.23) b
Intermittent claudication, n (%) 0 (0) 241 (100) – 109 (3.4) 80 (2.6)
Peripheral arterial disease, n (%) 0 (0) 241 (100) – 200 (6.4) 144 (8.0)b
Ankle–brachial index ,0.9, n (%) 14 (6) 178 (74) ,0.001 128 (4.1) 103 (5.7)b
eGFR (mL/min/1.73m2) 76.7+12.2 81.4+16.4 ,0.001 77.4+17.2 78.5+17.3
C-reactive protein (mg/dL) 0.26+0.33 0.63+1.05 ,0.001 – –
(0.10/0.13/0.28) (0.22/0.42/0.71)
Total cholesterol (mg/dL) 207.7+35.0 204.8+40.9 0.40 218.2+39.8 215.9+39.4
LDL-cholesterol (mg/dL) 135.6+33.0 132.9+37.0 0.39 127.9+32.5 135.9+34.8
HDL-cholesterol (mg/dL) 59.4+16.2 49.2+13.5 ,0.001 58.8+17.2 55.9+14.4
Triglycerides (mg/dL) 132+79 172+123 ,0.001 164+125 c 124+89c
(79/131/156) (95/135/213) (88/135/201) (72/104/150)
Lp(a), (mg/dL) 19.5+23.1 28.7+31.9 0.006 22.0+26.0 21.7+25.6
(4.2/10.1/28.5) (4.8/13.8/49.5) (4.9/11.1/28.5) (5.2/11.7/30.2)
LMW apo(a) phenotypes, n (%) 64 (26.0) 86 (35.7) 0.02 726 (23) 746 (24.4 )
Minor allele frequency of rs10455872, % 5.6 8.4 0.14 5.2 6.0
Data are n (%) or mean+ SD and (25th, median 75th percentile) where appropriate.
aComparison between cases and controls of the CAVASIC study were performed by x2 test, Fisher’s exact test, unpaired t-test or Mann–Whitney U test as appropriate.
bABI values in the KORA F4 study were only measured in 1796 individuals aged 52–81 years.
cBlood samples in KORA were collected in non-fasting state (KORA F3) or after an overnight fasting period (KORA F4).
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hypertensive, more frequently had CVD and a lower ABI. Mean Lp(a)
concentrations were significantly higher in patients than in controls
(28.7+31.9 vs. 19.5+23.1 mg/dL, P ¼ 0.006) and the frequency of
LMW apo(a) phenotypes was higher in patients than in controls (35.7
vs. 26.0%, P ¼ 0.02).
Table 2 shows the results from the logistic regression analyses. Since
nonlinear splines showed a linear relationship between SDlog-Lp(a) and
PAD (Supplementary material online, Figure S3), we performed analyses
with log-Lp(a) as a continuous variable. When data were only adjusted
for age, the OR for SDlog-Lp(a), LMW apo(a) phenotypes, and
rs10455872 was 1.30 (95%CI 1.09–1.56, P ¼ 0.005),1.60 (95%CI
1.08–2.36, P ¼ 0.019), and 1.62 (95%CI 0.97–2.17, P ¼ 0.06), respect-
ively. The associations remained stable or were only slightly attenuated
after further adjustment for current smoking and eGFR: OR ¼ 1.28
(95%CI 1.04–1.57, P ¼ 0.02) for SDlog-Lp(a), OR ¼ 1.65 (95%CI
1.07–2.57, P ¼ 0.03) for LMW apo(a) phenotypes, and OR ¼ 1.50
(95%CI 0.83–2.71, P ¼ 0.12) for rs10455872. After further adjustment
for hypertension, the association for SDlog-Lp(a) with PAD was un-
changed (OR ¼ 1.30; 95%CI 1.05–1.61; P ¼ 0.02), and was attenuated
for LMW apo(a) phenotypes (OR ¼ 1.42; 95%CI 0.90–2.25; P ¼ 0.14)
and the SNP (OR ¼ 1.27; 95%CI 0.68–2.38; P ¼ 0.45). Excluding
patients and controls with prevalent CVD did not change the estimates
of SDlog-Lp(a) or LMW in any of the models, but increased the OR for
rs10455872 (Table 2).
The IV regression obtained significant causal ORs from Lp(a) on
PAD (Model 1 and Model 2) that were even higher than the respective
observed regression estimates (Table 2). First-stage regression from
LMW apo(a) phenotypes and the SNP rs10455872 on Lp(a) yielded
a F-Statistic (2df) of 128, verifying that the LMW apo(a) phenotype
in combination with the LPA SNP are suitable instruments for Lp(a).
LMW phenotypes alone explained 33.7% of Lp(a) variance, and the
rs10455872 about 15%. In combination, 35% of Lp(a) variance were
explained.
3.2 Symptomatic and asymptomatic PAD
in the population-based KORA studies
In a next step, we investigated whether findings in the diseased popula-
tion of the CAVASIC study can be confirmed in the two population-
based studies of KORA. KORA F3 and F4 included 3157 and 3061
participants, respectively. Of these, 200 individuals in F3 and 144 indivi-
duals in F4 were diagnosed with symptomatic and/or asymptomatic
PAD. Intermittent claudication according to the Edinburgh question-
naire was present in 109 participants of KORA F3 and 80 participants
of KORA F4 (see Characteristics in Table 1). ABI measurements were
available for 3143 participants in KORA F3 and an ABI ,0.90 was
detected in 128 individuals (4.1%). In KORA F4, ABI was measured
only in 1796 study participants who were older than 51 years. An ABI
,0.9 was detected in 103 of these participants (5.7%).
Figure 2 shows the skewed distribution of Lp(a) concentration in a
combined analysis from KORA F3 und F4 with in total 6218 individuals
(Figure 2A). When Lp(a) concentration was analysed stratified by
groups of KIV repeat numbers (Figure 2B), we observed a major differ-
ence of Lp(a) concentrations between LMW and HMW apo(a) pheno-
type groups with about 5- to 10-fold higher median concentrations in
individuals with LMW than those with HMW apo(a) phenotype groups.
This strongly justifies the stratification in these two phenotype groups
for the further analyses. Median concentrations of Lp(a) also varied
strongly between genotype groups of SNP rs10455872: 9.9 mg/dL for
the AA, 50.3 mg/dL for the GA, and 90.9 mg/dL for the GG genotype.
In KORA F3, Lp(a) concentrations and the frequency of LMW apo(a)
phenotypes were slightly but non-significantly higher in participants with
compared with those without PAD (26.1+29.6 vs. 21.7+25.8 mg/dL,
P ¼ 0.07; 27.6 vs. 23.0%, P ¼ 0.14). However, in KORA F4, neither Lp(a)
concentrationsnor the frequencyofLMWapo(a)phenotypesdifferedsig-
nificantly between participants with and without PAD (Supplementary
material online, Table S1). Similar observations in the two cohorts were
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Logistic regression analysis on the association of SDlog-Lp(a) and LMW apo(a) phenotypes with PAD in the CAVASIC
study
SDlog-Lp(a) IVs: LMW apo(a) phenotype/SNP
rs10455872 (additive coding)
IV regression based on LMW
apo(a) phenotype and SNP
rs10455872
OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value
Model 1: adjusted for age
All patients and controls 1.30 (1.09, 1.56) 0.005 LMW 1.60 (1.08, 2.36) 0.02 1.47 (1.08, 1.99) 0.01
SNP 1.62 (0.97, 2.71) 0.06
Excluding CVDs 1.34 (1.08, 1.65) 0.007 LMW 1.60 (1.03, 2.48) 0.04 1.48 (1.05, 2.10) 0.03
SNP 1.80 (1.03, 3.18) 0.04
Model 2: adjusted for age, current smoking, and eGFR
All patients and controls 1.28 (1.04, 1.57) 0.02 LMW 1.65 (1.07, 2.57) 0.03 1.48 (1.05, 2.09) 0.03
SNP 1.50 (0.83, 2.71) 0.12
Excluding CVDs 1.37 (1.07, 1.75) 0.01 LMW 1.74 (1.05, 2.90) 0.03 1.56 (1.04, 2.32) 0.03
SNP 1.86 (0.95, 3.64) 0.07
Model 3: adjusted for age, current smoking, eGFR, and hypertension
All patients and controls 1.30 (1.05, 1.61) 0.02 LMW 1.42 (0.90, 2.25) 0.14 1.30 (0.94, 2.01) 0.14
SNP 1.27 (0.68, 2.38) 0.45
Excluding CVDs 1.40 (1.08, 1.80) 0.01 LMW 1.56 (0.92, 2.63) 0.10 1.41 (0.94, 2.12) 0.09
SNP 1.67 (0.82, 3.39) 0.16
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madefor intermittentclaudicationandforABI ,0.90(Supplementaryma-
terial online, Table S2–S3). Results from the logistic regression analyses
revealed no significant influence of SDlog-Lp(a) on these dichotomized
phenotypes in both studies and only a borderline association with LMW
apo(a)phenotypes inKORAF3(P0.09).TheORs for theSNPwerecon-
sistent with the causal assumption in both studies, but not significant
(Table 3 for KORAF3and KORA F4combinedand Supplementary mater-
ial online, Table S4 for additional individual study results).
Since dichotomizing a variable leads to a loss of valuable information,
we also performed linear regression analyses on continuous ABI to
capture the whole spectrum of ABI values and to improve statistical
power. The results from linear regression and linear mixed models are
provided in Table 3 for combined results of KORA F3 and KORA F4
and in Supplementary material online, Table S5 for individual study
results. Significant associations between increasing SDlog-Lp(a) concen-
trations, LMW apo(a) phenotype, and rs10455872 and lower ABI values
were found for KORA F3. The estimates for KORA F4 were similar but
did not reach statistical significance due to the smaller sample size. The
combined analysis of both cohorts revealed significant results. The
magnitude of these associations remained stable in the fully adjusted
model (SDlog-Lp(a) P ¼ 0.005; LMW apo(a) phenotypes P ¼ 0.02,
rs10455872 P ¼ 0.03) (Table 3). Causal effects derived from the IV re-
gression from SDlog-Lp(a) on ABI (Figure 1A) were all even stronger
than the respectiveobservedregressionestimates.Theywere significant
in all adjusted models in the combined analysis of KORAF3/F4 (fully
adjusted model: P ¼ 0.02) (Table 3). These results were similar when
the grouping into LMW/HMW apo(a) phenotypes were performed
based on the most strongly expressed apo(a) isoform in the western
blot and/or when the apo(a) isoform was analysed in a continuous
manner based on the number of K-IV repeats (see Supplementary
material online, Table S6).
In KORA F3 and F4, 28–29% of the Lp(a) concentration are explained
by the combination of rs10455872 and the LMW apo(a) phenotype, of
which 26.5% can be explained by LMW alone. The SNP alone without
considering apo(a) phenotypes explains 13.3% in KORA F4 and 17.7% in
KORA F3.
3.3 Sensitivity analyses and search
for the optimal Lp(a) threshold
For sensitivity analysis in the KORA studies (fully adjusted models), the
Lp(a) levels were dichotomized, applying a threshold value of 30 mg/dL
as well as the recently suggested threshold value of 50 mg/dL.21 We
observed significant associations with decreasing continuous ABI
values in KORA F3 for Lp(a) .30 mg/dL (b ¼ 20.016; P ¼ 0.01) and
Lp(a) .50 mg/dL (b ¼ 20.028; P ¼ 0.0002). No significant associa-
tion was observed for Lp(a) .30 mg/dL for KORA F4 (b ¼ 20.009,
P ¼ 0.28) while the analysis with a threshold of 50 mg/dL was significant
(b ¼ 20.023; P ¼ 0.03). In the CAVASIC study, the same trendcould be
observed with a higher OR for the threshold of 50 mg/dL (OR ¼ 2.657,
P ¼ 0.001) compared with 30 mg/dL (see Supplementary material
online, Table S7 for detailed results for all dichotomized analyses).
These results suggest that the higher threshold of 50 mg/dL seems to
be more relevant for PAD than 30 mg/dL. To further support this
hypothesis, optimal cutpoints were derived for all three studies applying
the AIC criterion. This analysis resulted in an optimal Lp(a) threshold of
54 mg/dL in the linear regressionon ABI in KORA F3, 69 mg/dL in KORA
F4, and 53 mg/dL in the logistic regression on PAD in the CAVASIC
study. However, nonlinear P-Splines do not contradict the linear
assumption in general (Supplementary material online, Figure S1–S3).
Further sensitivity analyses were performed applying different exclu-
sion criteria: when we excluded individuals with prevalent CVDs, we
observed similar results with slightly attenuated estimates. When we
excluded individuals with ABI values above 1.30 estimates were slightly
weakened as well.
Additional analysis were performed adjusting the association of LMW
apo(a) phenotypes on ABI in the KORA studies or PAD in CAVASIC for
SDlog-Lp(a). As expected, all estimates and ORs were attenuated and
P-values were not significant any more (Supplementary material
online, Tables S8 and S9).
Finally, we analysed a possible sex interaction in both KORA studies
and could not find any evidence of an interaction. P-values for inter-
action for the main analyses were 0.88 and 0.42 for KORA F3 and F4,
respectively.
4. Discussion
In the present study, we investigated the association between Lp(a) con-
centrations, LMW apo(a) phenotypes, the rs10455872 SNP in the LPA
gene, and various outcome variables related to PAD in three independ-
ent studies. The main findings are: (i) a significant association of SDlog-
Lp(a) concentrations, LMW apo(a) phenotypes, and rs10455872 with
symptomatic intermittent claudication was found in a case–control
study. An association with peripheral atherosclerosis phenotypes was
Figure 2 (A) Distribution of Lp(a) concentration in 6218 individuals
from the two population-based studies KORA F3 and F4. (B) Median
Lp(a) concentrations in various groups of subjects stratified by the
number of KIV repeats and genotypes of SNP rs10455872; 11–22
KIV repeats are considered as low molecular weight (LMW) or small
isoforms and those with .22 KIV repeats are considered as high
molecular weight (HMW) or large apo(a) isoforms.
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Table 3 Results of logistic and linear mixed regression models and IV regression for SDlog-Lp(a) and LMW apo(a) phenotypes in KORA F3 and F4 combined
Number of individualsa all (for
dichotomized variables: those with
endpoint 5 ‘yes’)
SDlog-Lp(a) IVs: LMW apo(a) phenotype/SNP rs10455872
(additive coding)
IV regression based on LMW apo(a)
phenotype and SNP rs10455872
OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value
Mixed logistic regressionb on PAD, intermittent claudication and ABI,0.90
PADc 4905 (339) 1.05 (0.93,1.17) 0.43 LMW 1.13 (0.87, 1.46) 0.37 1.10 (0.88, 1.36) 0.40
SNP 1.27 (0.89, 1.81) 0.19
Intermittent claudication 6208 (187) 1.08 (0.93,1.25) 0.33 LMW 1.19 (0.85, 1.67) 0.30 1.07 (0.80, 1.42) 0.65
SNP 1.10 (0.68, 1.80) 0.69
ABI , 0.9 4914 (227) 1.06 (0.92,1.21) 0.42 LMW 1.18 (0.86, 1.61) 0.30 1.15 (0.89, 1.49) 0.28
SNP 1.36 (0.89, 2.07) 0.16
beta (95%CI) P-value beta (95%CI) P-value beta (95%CI) P-value
Mixed linear regression on continuous ABI
Model 1d 4914 20.007 (20.011, 20.002) 0.002 LMW 20.013 (20.023, 20.003) 0.01 20.011 (20.019, 20.003) 0.009
SNP 20.014 (20.028, 0.000) 0.05
Model 2e 4724 20.006 (-0.010, 20.002) 0.005 LMW 20.011 (20.021, 20.001) 0.02 20.010 (20.018, 20.002) 0.02
SNP 20.016 (20.030, 20.002) 0.03
aNumber of individuals are based on those with available data on Lp(a) and apo(a) phenotypes.
bLogistic mixed models are adjusted for age and sex.
cPAD defined as either ABI,0.9 or intermittent claudication or both.
dModel 1: adjusted for age and sex.
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confirmed in the population-based cohort studies KORA F3 and F4 only
when theanalysiswasdoneonacontinuous scale for the ABI; (ii) theana-
lysis in more than 6000 subjects from the general population demon-
strated a clear threshold effect in Lp(a) concentrations between small
and large apo(a) phenotype groups. This strongly justifies the stratifica-
tion in these two isoform groups which are the basis for (iii) the final IV
regression analysis which strongly supported causality between Lp(a)
concentrations and PAD phenotypes; (iv) the search for the optimal
cut-off that predicts PAD phenotypes revealed that rather higher
Lp(a) concentrations above 50 mg/dL might be better suitable for
these PAD phenotypes.
While numerous studies have addressed the relation between Lp(a)
and coronary artery disease (CAD),3– 6 only a limited number of
studies have evaluated the association with PAD22–32 and only three
case–control studies have considered apo(a) phenotypes.22– 24 The
main characteristics and the results of these studies can be found in Sup-
plementary material online, Table S10. In summary, most of them
described an association between Lp(a) concentrations and PAD
defined by a broad range of criteria. This association was especially
strong in case–control studies including our CAVASIC Study which typ-
ically considered patients with symptomatic PAD. Previous prospective,
population-based studies provided a less clearpictureand not all of them
described an association of Lp(a) concentrations with outcomes (Sup-
plementary material online, Table S10). In the present population-based
studies of KORA F3 and F4, we observed significant associations with
PAD only when the entire spectrum of ABI values without dichotomiza-
tion and therefore more power was used for the data analysis.
The study design might explain differences between observations in
clinical samples and general population samples. The former, such as
the CAVASIC Study, consist solely of patients with a pronounced symp-
tomatic phenotype while in the general population studies, such as
KORA, a much smaller number of participants are diagnosed with symp-
tomatic PAD according to the Edinburgh questionnaire and they usually
show less severe phenotypes. Furthermore, the latter cover a wider age
range including more individuals that are younger and have the potential
to develop symptomatic PAD in the future and thereby dilute the
expected associations. Therefore, in the KORA cohorts, the continuous
ABI might be more relevant as it reflects not only symptomatic but also
asymptomaticPADand isprobablya surrogateof theconditionof theper-
ipheral vascular system. Moreover, the strict and commonly used cut-off
value of an ABI ,0.90 for the definition of PAD has recently been ques-
tioned since individuals with ABI values between 0.90 and 1.09 already
showed a higher incidence of mobility loss over a period of 5 years com-
pared with persons with ABI values above 1.09.33 Additionally, an inverse
linear relationship between continuous ABI and cardiovascular outcomes
has been reported showing that ABI is predictive for incident myocardial
infarctions as well as cardiovascular and total mortality.10 This supports
that ABI measured on a continuous scale may provide relevant informa-
tion on the disease severity at values also slightly above 0.90.
We found very strong associations with ABI when Lp(a) was dichot-
omized at50 mg/dL. Optimal data-driven thresholds were found tobe at
54oreven69 mg/dL in the KORA studies and 53 mg/dL for symptomatic
PAD in CAVASIC. This is in line with similar observations on Lp(a) levels
and stroke in a recent meta-analysis that found Lp(a) only significantly
associated with stroke when levels were above 50 mg/dL.4 Therefore,
it seems that the effect of Lp(a) is stronger on the coronary arteries
than on cerebrovascular or lower extremity vessels.
The two most important aspects of our analysis were based on the in-
vestigation of the genetically determined apo(a) phenotypes in the
investigated cohorts which allowed to extrapolate on causal aspects.
First, it is the largest study so far that analysed the apo(a) isoforms
expressed in plasma and not on DNA level. This is of utmost importance
since in about half to one-third of individuals only one isoform is
expressed in plasma although two different alleles are present at the
DNA level.34 With regard to risk prediction, it might be questioned
why one should be interested in an allele that is not expressed at all in
plasma when the site of pathogenic action of Lp(a) is expected to be
in the vascular system.35 The second aspect is that the availability of
the apo(a) phenotypes allowed us to apply the commonly used Mendel-
ian Randomization approach to support causality. In addition, the SNP
rs10455872 in the LPA gene has been determined and included in the
analyses. Since this SNP is rather rare (MAF5–7%) and tags less
than half of the short isoforms,35 it explains a rather small amount of
Lp(a) variance in addition to LMW apo(a) phenotypes. The Mendelian
Randomization approach is based on the fact that it is randomly deter-
mined which of the two isoforms and/or alleles of rs10455872 from
the father as well as from the mother will be transmitted to the child
at the time of conception. Since the transmitted alleles are of lifelong
persistence, these alleles determine to a certain extent also whether a
person is exposed to high Lp(a) levels and therefore to a high athero-
sclerosis risk. Thus, the association between apo(a) isoforms and/or
alleles of the SNP and PAD phenotypes is less likely to be influenced
by reverse causation or confounding. Reverse causation would mean
that PAD influences the polymorphisms, which can practically be
excluded. Confounding would mean that, e.g. a lifestyle factor such as
smoking is associated with the disease (which is often the case) as well
as with the polymorphisms (which is less probable).36 Therefore, this
method is well appropriate to underline a causal relationship between
Lp(a) andPAD/ABIwhich is hardlypossiblewithconventional epidemio-
logical observation studies. We applied and extended this Mendelian
Randomization approach for PAD using an IV regression technique to
assess effects of Lp(a) levels which are predicted by LMWapo(a) pheno-
types and rs10455872 genotypes. Therefore, these estimates can be
interpreted as the causal effects of Lp(a) on PAD/ABI. Our findings indi-
cated that these causal effects are even higher than those that could be
observed in theordinary regressionmodels fromLp(a)on the respective
outcomes. Only three case–control studies so far22– 24 investigated the
association of LMW apo(a) phenotypes with PAD of various definitions.
In two of these, a significant association was observed.23,24 Few other
studies analysed SNPs in the LPA gene region and also observed a signifi-
cant association with PAD phenotypes (Supplementary material online,
Table S10).37 –39 However, none of these studies did apply IV regression
to formally estimate causal effects.
4.1 Strength and limitations of the study
A strength of our study is that apo(a) phenotypes were determined in all
samples of the CAVASIC study and the two KORA studies in one labora-
tory. It is therefore by far the largest study up to now which analysed the
apo(a) phenotypes by western blot. The use of the apo(a) phenotype in
the data analysis allows the application of a Mendelian Randomization
approach including an IV regression technique which supports the
causal relationship between Lp(a) concentrations and PAD.
The analyses are limited by the cross-sectional study design of
CAVASIC and KORA, which precludes an assessment of the predictive
properties for Lp(a) concentrations and LMW apo(a) phenotypes over
time and in studies of cross-sectional design a survival bias cannot be en-
tirely excluded. Finally, we might lack statistical power for the PAD ana-
lysis in the KORA studies that included individuals with a wide age range
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and probably a considerable number of subjects who are still too young
to show symptomatic PAD. These subjects might have diluted the
associations.
5. Conclusions
Our analyses in three independent populations point to a significant
association between Lp(a) concentrations, LMW apo(a) phenotypes,
and one SNP within the LPA gene with symptomatic and asymptomatic
PAD. This association is probably of causal nature since the genetically
determined apo(a) phenotypes and the investigated SNP that influence
the Lp(a) concentrations to a large extent are indeed associated with
these PAD phenotypes.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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